Validation of Brain Oxygenation Monitor on Pediatric Patients
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Validation of the CAS Medical System, Inc. FORE-SIGHT Near-Infrared Spectroscopy (NIRS) Monitor in Pediatric Subjects for Viscerosomatic Applications|
- Accuracy of sensor [ Time Frame: Data collected from individual participants over 4 hour timeframe. Data from cohort of subjects collected over 24 month period. ] [ Designated as safety issue: No ]Correlation between displayed tissue sensor value and measured blood values of tissue oxygen saturation, from which the degree of sensor accuracy is derived.
- Degree of concordance between NIRS StO2 and mean mixed venous oxygen saturation [ Time Frame: Data collected from individual participants over 4 hour timeframe. ] [ Designated as safety issue: No ]
- Difference between NIRS viscerosomatic StO2 and NIRS cerebral SctO2 [ Time Frame: Data collected from individual participants over 4 hour timeframe. ] [ Designated as safety issue: No ]
- Degree of concordance between NIRS hemoglobin concentration per volume of viscerosomatic tissue (TotalHb) and hematocrit (HCT) /hemoglobin (HGB) measured from arterial blood. [ Time Frame: Data collected from individual participants over 4 hour timeframe. ] [ Designated as safety issue: No ]
|Study Start Date:||February 2009|
|Estimated Study Completion Date:||December 2016|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Pediatric patients presenting for cardiac catheterization.
Device: CAS NIRS FORE-SIGHT oximeter
Comparison of non-invasive tissue oxygen saturation with blood sample-derived (calculated) tissue oxygen saturation.
NIRS cerebral oximeters are FDA-approved devices used to measure oxygen saturation within the brain, in a similar manner to pulse oximeters that measure the oxygen saturation in the finger tip. The sensor pads are placed on the surface of the forehead and shine near-infrared light through the skull and brain tissue from which the brain tissue oxygen saturation is estimated. The same principles can be applied when the sensor pads are placed over the internal organs of the abdomen, for example, the liver. Currently the only way to accurately measure the oxygen saturation of internal organs is by the invasive placement of intravenous lines into the blood vessels of that organ. This study will determine if the NIRS sensors can reliably estimate the tissue oxygen saturation non-invasively by placing the pad over the skin of the abdomen.
The study will be conducted in pediatric patients who are undergoing cardiac catheterization, a procedure in which invasive lines are placed in order to get information about the heart. The procedure is always conducted under general anesthesia. During the cardiac catheterization procedure blood samples are routinely taken for oxygen saturation analysis. In the study two oximeter sensor pads will be placed on the forehead (one on each side) and two further oximeter sensor pads will be placed on the abdominal wall. The oxygen saturation values from all oximeter sensors will be recorded continuously throughout the cardiac catheterization procedure and will be compared to the oxygen saturation values from the blood samples. In addition to the routine blood samples taken as part of the cardiac catheterization, one blood sample will be taken when the invasive line is within the right hepatic (liver) vein.
The information from this study will determine how well the oximeter sensors estimate the oxygen saturation of both the internal organs (StO2) and the blood returning to the heart (mean mixed venous oxygen saturation).
Please refer to this study by its ClinicalTrials.gov identifier: NCT00849940
|Contact: David MacLeod, FRCAemail@example.com|
|United States, North Carolina|
|Duke University Health System||Recruiting|
|Durham, North Carolina, United States, 27710|
|Contact: David B MacLeod, FRCA 919-812-3201 firstname.lastname@example.org|
|Principal Investigator: David B MacLeod, FRCA|
|Principal Investigator:||David B MacLeod, FCRA||Duke University Health System|